• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

耐碳青霉烯类:毒力因子、分子流行病学及治疗选择的最新进展

Carbapenem-Resistant : Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options.

作者信息

Karampatakis Theodoros, Tsergouli Katerina, Behzadi Payam

机构信息

Microbiology Department, Papanikolaou General Hospital, 57010 Thessaloniki, Greece.

Microbiology Department, Agios Pavlos General Hospital, 55134 Thessaloniki, Greece.

出版信息

Antibiotics (Basel). 2023 Jan 21;12(2):234. doi: 10.3390/antibiotics12020234.

DOI:10.3390/antibiotics12020234
PMID:36830145
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9952820/
Abstract

is a Gram-negative opportunistic pathogen responsible for a variety of community and hospital infections. Infections caused by carbapenem-resistant (CRKP) constitute a major threat for public health and are strongly associated with high rates of mortality, especially in immunocompromised and critically ill patients. Adhesive fimbriae, capsule, lipopolysaccharide (LPS), and siderophores or iron carriers constitute the main virulence factors which contribute to the pathogenicity of . Colistin and tigecycline constitute some of the last resorts for the treatment of CRKP infections. Carbapenemase production, especially carbapenemase (KPC) and metallo-β-lactamase (MBL), constitutes the basic molecular mechanism of CRKP emergence. Knowledge of the mechanism of CRKP appearance is crucial, as it can determine the selection of the most suitable antimicrobial agent among those most recently launched. Plazomicin, eravacycline, cefiderocol, temocillin, ceftolozane-tazobactam, imipenem-cilastatin/relebactam, meropenem-vaborbactam, ceftazidime-avibactam and aztreonam-avibactam constitute potent alternatives for treating CRKP infections. The aim of the current review is to highlight the virulence factors and molecular pathogenesis of CRKP and provide recent updates on the molecular epidemiology and antimicrobial treatment options.

摘要

是一种革兰氏阴性机会致病菌,可导致多种社区和医院感染。耐碳青霉烯类肺炎克雷伯菌(CRKP)引起的感染对公共卫生构成重大威胁,且与高死亡率密切相关,尤其是在免疫功能低下和重症患者中。黏附菌毛、荚膜、脂多糖(LPS)以及铁载体构成了有助于肺炎克雷伯菌致病性的主要毒力因子。黏菌素和替加环素是治疗CRKP感染的一些最后手段。碳青霉烯酶的产生,尤其是KPC碳青霉烯酶和金属β-内酰胺酶(MBL),是CRKP出现的基本分子机制。了解CRKP出现的机制至关重要,因为它可以决定在最近推出的抗菌药物中选择最合适的抗菌剂。普拉唑米星、依拉环素、头孢地尔、替莫西林、头孢洛扎坦-他唑巴坦、亚胺培南-西司他丁/瑞来巴坦、美罗培南-瓦博巴坦、头孢他啶-阿维巴坦和氨曲南-阿维巴坦是治疗CRKP感染的有效替代药物。本综述的目的是强调CRKP的毒力因子和分子发病机制,并提供分子流行病学和抗菌治疗选择的最新进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/887b/9952820/23174a7c54b0/antibiotics-12-00234-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/887b/9952820/23174a7c54b0/antibiotics-12-00234-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/887b/9952820/23174a7c54b0/antibiotics-12-00234-g001.jpg

相似文献

1
Carbapenem-Resistant : Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options.耐碳青霉烯类:毒力因子、分子流行病学及治疗选择的最新进展
Antibiotics (Basel). 2023 Jan 21;12(2):234. doi: 10.3390/antibiotics12020234.
2
Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.希腊产碳青霉烯酶肺炎克雷伯菌分离株的流行病学和头孢他啶-阿维巴坦、美罗培南-法硼巴坦、亚胺培南-雷利巴坦、依拉环素、硫酸普拉米星及对照药物的体外活性
Infection. 2022 Apr;50(2):467-474. doi: 10.1007/s15010-021-01735-1. Epub 2021 Dec 2.
3
Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.抗菌药物耐药性和新型抗菌药物时代的尿路感染治疗。
Postgrad Med. 2020 Apr;132(3):234-250. doi: 10.1080/00325481.2019.1680052. Epub 2019 Oct 24.
4
Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.新型β-内酰胺/β-内酰胺酶抑制剂组合及头孢地尔在重症患者中应用的理论依据与证据
Ann Intensive Care. 2023 Jul 18;13(1):65. doi: 10.1186/s13613-023-01153-6.
5
Carbapenem-resistant hypermucoviscous clinical isolates from a tertiary hospital in China: Antimicrobial susceptibility, resistance phenotype, epidemiological characteristics, microbial virulence, and risk factors.中国一家三级医院耐碳青霉烯类超黏液型临床分离株:抗菌药物敏感性、耐药表型、流行病学特征、微生物毒力和危险因素。
Front Cell Infect Microbiol. 2022 Dec 21;12:1083009. doi: 10.3389/fcimb.2022.1083009. eCollection 2022.
6
Carbapenemase producing : implication on future therapeutic strategies.产碳青霉烯酶:对未来治疗策略的影响
Expert Rev Anti Infect Ther. 2022 Jan;20(1):53-69. doi: 10.1080/14787210.2021.1935237. Epub 2021 Jun 3.
7
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔:一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
8
Meropenem/vaborbactam activity : a new option for carbapenemase (KPC)-producing treatment.美罗培南/法硼巴坦活性:产碳青霉烯酶(KPC)治疗的新选择。
Future Microbiol. 2021 Nov;16:1261-1266. doi: 10.2217/fmb-2021-0007. Epub 2021 Oct 22.
9
Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies.血液系统恶性肿瘤患者碳青霉烯类耐药感染治疗的最新进展
Expert Rev Anti Infect Ther. 2024 Dec;22(12):1055-1071. doi: 10.1080/14787210.2024.2408746. Epub 2024 Sep 29.
10
Carbapenem-Resistant Among Patients with Ventilator-Associated Pneumonia: Evaluation of Antibiotic Combinations and Susceptibility to New Antibiotics.呼吸机相关性肺炎患者对碳青霉烯类抗生素的耐药性:抗生素联合用药评估及对新型抗生素的敏感性
Infect Drug Resist. 2022 Jul 6;15:3537-3548. doi: 10.2147/IDR.S371248. eCollection 2022.

引用本文的文献

1
Urinary Multidrug-Resistant : Essential Oil Countermeasures in a One Health Case Report.泌尿道多重耐药:“同一健康”案例报告中的精油应对措施
Microorganisms. 2025 Aug 1;13(8):1807. doi: 10.3390/microorganisms13081807.
2
Epidemiology of Carbapenem-Resistant Klebsiella Pneumoniae Co-Producing MBL and OXA-48-Like in a Romanian Tertiary Hospital: A Call to Action.罗马尼亚一家三级医院中同时产金属β-内酰胺酶和OXA-48样酶的耐碳青霉烯类肺炎克雷伯菌的流行病学:行动呼吁
Antibiotics (Basel). 2025 Aug 1;14(8):783. doi: 10.3390/antibiotics14080783.
3
Updates on therapeutic targeting of diguanylate cyclase for addressing bacterial infections: A comprehensive review.

本文引用的文献

1
Molecular Detection of Mutation in Clinical Strains of ..临床菌株中突变的分子检测
Iran J Public Health. 2022 Oct;51(10):2334-2339. doi: 10.18502/ijph.v51i10.10992.
2
A comprehensive review on lactoferrin: a natural multifunctional glycoprotein.乳铁蛋白:一种天然多功能糖蛋白的综合综述。
Food Funct. 2022 Nov 28;13(23):11954-11972. doi: 10.1039/d2fo02371g.
3
Prevalence and incidence of carbapenem-resistant K. pneumoniae colonization: systematic review and meta-analysis.碳青霉烯类耐药肺炎克雷伯菌定植的流行率和发生率:系统评价和荟萃分析。
针对细菌感染的二鸟苷酸环化酶治疗靶点的最新进展:全面综述
World J Microbiol Biotechnol. 2025 Aug 26;41(9):317. doi: 10.1007/s11274-025-04512-6.
4
Genome Sequencing and Comparative Genomic Analysis of Multidrug-Resistant in a Neurological Intensive Care Unit.神经重症监护病房中耐多药菌的全基因组测序及比较基因组分析
Infect Drug Resist. 2025 Aug 12;18:4067-4086. doi: 10.2147/IDR.S528440. eCollection 2025.
5
Metagenome Analysis Reveals Changes in Gut Microbial Antibiotic Resistance Genes and Virulence Factors in Reintroduced Giant Pandas.宏基因组分析揭示了放归大熊猫肠道微生物抗生素抗性基因和毒力因子的变化。
Microorganisms. 2025 Jul 9;13(7):1616. doi: 10.3390/microorganisms13071616.
6
Fumarate and nitrate reduction regulator (FNR) modulates hypermucoviscosity and virulence in hypervirulent through anaerobic adaptation.富马酸和硝酸盐还原调节因子(FNR)通过厌氧适应调节高毒力菌株的高黏液性和毒力。
Virulence. 2025 Dec;16(1):2536186. doi: 10.1080/21505594.2025.2536186. Epub 2025 Jul 28.
7
Prevalence of polymyxin heteroresistance in Klebsiella pneumoniae under sustained antibiotic selection during experimental evolution.实验进化过程中持续抗生素选择下肺炎克雷伯菌多粘菌素异质性耐药的发生率
Arch Microbiol. 2025 Jul 21;207(9):201. doi: 10.1007/s00203-025-04405-0.
8
Whole-Genome Sequencing and Bioinformatics Analysis of ESBL- producing Klebsiella pneumoniae in a Ghanaian teaching hospital.加纳一家教学医院产超广谱β-内酰胺酶肺炎克雷伯菌的全基因组测序及生物信息学分析
BMC Microbiol. 2025 Jul 2;25(1):401. doi: 10.1186/s12866-025-04101-5.
9
Containment of a carbapenem-resistant in an intensive care unit during the COVID-19 pandemic.在新型冠状病毒肺炎大流行期间,重症监护病房对耐碳青霉烯类菌的控制。
Front Public Health. 2025 Jun 17;13:1557068. doi: 10.3389/fpubh.2025.1557068. eCollection 2025.
10
Predictive model for carbapenem-resistant Klebsiella pneumoniae bloodstream infection based on a nomogram: a retrospective study.基于列线图的耐碳青霉烯类肺炎克雷伯菌血流感染预测模型:一项回顾性研究
BMC Res Notes. 2025 Jul 1;18(1):265. doi: 10.1186/s13104-025-07325-w.
Syst Rev. 2022 Nov 15;11(1):240. doi: 10.1186/s13643-022-02110-3.
4
Next-Generation Sequencing of Carbapenem-Resistant Strains Isolated from Patients Hospitalized in the University Hospital Facilities.从大学医院设施住院患者中分离出的耐碳青霉烯菌株的下一代测序
Antibiotics (Basel). 2022 Nov 3;11(11):1538. doi: 10.3390/antibiotics11111538.
5
The making of hypervirulent Klebsiella pneumoniae.产超毒力肺炎克雷伯菌的形成。
J Clin Lab Anal. 2022 Dec;36(12):e24743. doi: 10.1002/jcla.24743. Epub 2022 Nov 8.
6
Iron in infectious diseases friend or foe?: The role of gut microbiota.传染病中的铁:朋友还是敌人?肠道微生物群的作用。
J Trace Elem Med Biol. 2023 Jan;75:127093. doi: 10.1016/j.jtemb.2022.127093. Epub 2022 Oct 8.
7
Clinical and Molecular Characterizations of Carbapenem-Resistant Klebsiella pneumoniae Causing Bloodstream Infection in a Chinese Hospital.中国某医院血流感染碳青霉烯类耐药肺炎克雷伯菌的临床与分子特征
Microbiol Spectr. 2022 Oct 26;10(5):e0169022. doi: 10.1128/spectrum.01690-22. Epub 2022 Oct 3.
8
Characterization of Carbapenemase-Producing Isolates from Two Romanian Hospitals Co-Presenting Resistance and Heteroresistance to Colistin.来自罗马尼亚两家医院的产碳青霉烯酶菌株的特征分析,这些菌株同时对黏菌素呈现耐药性和异质性耐药。
Antibiotics (Basel). 2022 Aug 30;11(9):1171. doi: 10.3390/antibiotics11091171.
9
Capsule type defines the capability of Klebsiella pneumoniae in evading Kupffer cell capture in the liver.囊壳类型决定了肺炎克雷伯菌逃避肝脏库普弗细胞捕获的能力。
PLoS Pathog. 2022 Aug 1;18(8):e1010693. doi: 10.1371/journal.ppat.1010693. eCollection 2022 Aug.
10
Polymyxin Resistance in Clinical Isolates of in Brazil: Update on Molecular Mechanisms, Clonal Dissemination and Relationship With KPC-Producing Strains.巴西临床分离株中的多粘菌素耐药性:分子机制、克隆传播及与产KPC菌株关系的最新进展
Front Cell Infect Microbiol. 2022 Jul 15;12:898125. doi: 10.3389/fcimb.2022.898125. eCollection 2022.